Clinical Toolkit

  • The most common signs and symptoms of COVID-19 are fever, cough, and shortness of breath. Less common symptoms include nausea, muscle ache, confusion, headache, and sore throat.

  • Pre-existing comorbid conditions that increase the likelihood of severe illness with COVID-19 include cardiovascular disease, diabetes, chronic respiratory disease, hypertension, cancer, and obesity.

  • It is estimated that roughly 15% of people infected with the new coronavirus will develop severe disease requiring hospitalization, and another 5% will become critically ill.

Clinical Care Toolkit Introduction

COVID-19 has created unprecedented challenges for the health care community worldwide. Recently, the emergence of novel therapeutic agents and vaccines against COVID-19 has significantly improved patient outcomes and reduced the number of individuals infected with SARS-CoV-2. In order to best serve patients, clinicians require up-to-date resources on how to utilize new therapies and the latest on changes to treatment recommendations. This Clinical Care Toolkit aims to provide health care providers with the most recent information on monoclonal antibodies, vaccines, and other agents for the treatment and prevention of COVID-19.

Click on the links below to begin exploring the COVID FRONTLINE initiative.

References

  1. Centers for Disease Control and Prevention (CDC). Learn About Age-Related Macular Degeneration. https://www.cdc.gov/features/healthyvisionmonth/index.html. Accessed March 6, 2020.
  2. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147-1159.
  3. American Macular Degeneration Foundation [AMDF website]. Wet Macular Degeneration. https://www.macular.org/wet-amd. Accessed March 6, 2020.
  4. Fine AM. Earliest symptoms caused by neovascular membranes in the macular. Arch Ophthal. 1986;104:513-514.
  5. National Institutes of Health (NIH)/National Eye Institute (NEI). AMD Data and Statistics. https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/age-related-macular-degeneration-amd-data-and-statistics. Accessed April 1, 2020.
Menu

Updates in the Treatment and Prevention of COVID-19​

Casirivimab and Imdevimab Approved in Japan for the Treatment of Mild-to-Moderate COVID-19

Japan’s Ministry of Health, Labour and Welfare (MHLW) has fully approved the combination of casirivimab and imdevimab to treat patients with mild-to-moderate COVID-19. This marks the first time a monoclonal-antibody cocktail has received full approval to treat COVID-19. This combination therapy is currently authorized for emergency use in more than 20 countries, including the United States, European Union, India, Switzerland, and Canada. The monoclonal antibody cocktail was approved in Japan after results from a phase 3 trial showed a 70% reduction in the risk of hospitalization or death in high-risk non-hospitalized patients who received casirivimab and imdevimab. The MHLW also reviewed results from a phase 1 trial that analyzed the safety, tolerability, and pharmacokinetics of the combination therapy in Japanese subjects. Multiple analyses have shown that casirivimab and imdevimab retain potency against circulating variants of concern, including Delta (B.1.162.2, first seen in India), Gamma (P.1, first seen in Brazil), and Beta (B.1.351, first seen in South Africa).

Reference

https://newsroom.regeneron.com/news-releases/news-release-details/japan-becomes-first-country-approve-regeneron-antibody-cocktail